Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.57 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 8/20 | 0.55 |
| ▸ | IGF1R | P08069 | 2/20 | 0.55 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27556467 | 0.78 | CDK2 (0.81) | DYRK1AMAPK8MAPK9IRAK4CDK2 | |
| SCHEMBL3554702 | 0.77 | MAPK9 (0.43) | DYRK1AMAPK8MAPK9MAPK10DYRK2 | |
| SCHEMBL182990 | 0.76 | DYRK1A (0.66) | DYRK1AMAPK8MAPK9IRAK4MAPK10 | |
| SCHEMBL4804170 | 0.76 | DYRK1A (0.66) | DYRK1AMAPK8MAPK9IRAK4MAPK10 | |
| SCHEMBL3557515 | 0.76 | DYRK1A (0.65) | DYRK1AMAPK8MAPK9IRAK4MAPK10 | |
| SCHEMBL183113 | 0.73 | MAPK9 (1.00) | DYRK1AMAPK8MAPK9IRAK4MAPK10 | |
| SCHEMBL7877100 | 0.73 | MAPK9 (1.00) | DYRK1AMAPK8MAPK9IRAK4MAPK10 | |
| SCHEMBL3550672 | 0.73 | DRD1 (0.45) | DYRK1AMAPK8MAPK9DYRK2DYRK1B | |
| SCHEMBL15756734 | 0.72 | FLT3 (0.61) | CDK2CDK1CDK4 | |
| SCHEMBL27565115 | 0.72 | CDK2 (0.78) | DYRK1AMAPK8MAPK9IRAK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | DYRK1A 483/4885MAPK8 584/4885MAPK9 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.